12:39 PM
 | 
Feb 17, 2017
 |  BioCentury  |  Finance

NexImmune’s next act

How differing opinions on pipeline strategy led to NexImmune buyout

Management’s and investors’ different views about what product to develop first was the catalyst for the sale of immuno-oncology play NexImmune Inc. to a new syndicate led by Sol Barer, chairman of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA).

On Feb. 14, the new syndicate acquired all NexImmune shares held by New Enterprise Associates (NEA), Amgen Ventures and Pfizer Venture Investments for an undisclosed sum. The new investor group also put additional undisclosed capital in NexImmune...

Read the full 376 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >